Drug Trial Radar · NCT06799286
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
May 7, 2025
Primary completion
Sep 9, 2026
Study completion Sep 9, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).
Conditions
- Small Cell Lung Carcinoma
Interventions
BMS-986489Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to 19 months after last participant's first treatment
- Number of participants with Serious AEs (SAEs)Time frame: Up to 19 months after last participant's first treatment
- Number of participants with AEs leading to discontinuation of study treatmentTime frame: Up to 19 months after last participant's first treatment
- Number of participants with select AEsTime frame: Up to 19 months after last participant's first treatment
- Number of participants with immune-mediated AEs (IMAEs)Time frame: Up to 19 months after last participant's first treatment
- Number of deathsTime frame: Up to 19 months after last participant's first treatment
- Number of participants with laboratory abnormalitiesTime frame: Up to 19 months after last participant's first treatment
- Maximum observed concentration (Cmax) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
- Time of maximum observed concentration (Tmax) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
- Trough observed plasma concentration (Ctrough) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
- Concentration at the end of a dosing interval (Ctau) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
- Average concentration over a dosing interval ([AUC(TAU)/TAU]) (Cavg(TAU)) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
- Area under the concentration-time curve within one dosing interval (AUC(TAU)) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
- Total body clearance (CLT) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
- Observed concentration at end of infusion (Ceoi) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 0002
Shanghai, China
Local Institution - 0004
Beijing, Beijing Municipality, China
Local Institution - 0003
Jinan, Shandong, China
Local Institution - 0001
Linyi, Shandong, China
Local Institution - 0005
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.